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Abstract
Phosphopeptide pTyr-Glu-Glu-Ile (pYEEI) has been introduced as an optimal Src SH2 domain
ligand. Peptides, Ac-K(IDA)pYEEIEK(IDA) (1), Ac-KpYEEIEK (2), Ac-K(IDA)pYEEIEK (3),
and Ac-KpYEEIEK(IDA) (4), containing 0–2 iminodiacetate (IDA) groups at the N- and C-terminal
lysine residues were synthesized and evaluated as the Src SH2 domain binding ligands. Fluorescence
polarization assays showed that peptide 1 had a higher binding affinity (Kd = 0.6 µM) to the Src SH2
domain when compared with Ac-pYEEI (Kd = 1.7 µM), an optimal Src SH2 domain ligand, and
peptides 2−4 (Kd = 2.9–52.7 µM). The binding affinity of peptide 1 to the SH2 domain was reduced
by more than two fold (Kd = 1.6 µM) upon addition of Ni2+ (300 µM), possibly due to modest
structural effect of Ni2+ on the protein as shown by circular dichroism experimental results. The
binding affinity of 1 was restored in the presence of EDTA (300 µM) (Kd = 0.79 µM). These studies
suggest that peptides containing IDA groups may be used for designing novel SH2 domain binding
ligands.
Keywords
phosphopeptides; metal chelation; iminodiacetate group; SH2 domain; UV titration; fluorescence
polarization; circular dichroism
1.0. Introduction
Src, one of the first studied non-receptor tyrosine kinases, has been implicated in the genesis
and progression of multiple types of human diseases including colon, breast, lung cancers,
osteoporosis, and inflammation-mediated bone loss [1,2]. Src tyrosine kinase contains three
major domains, in the order from N- to C-terminal, two regulatory Src homology (SH) domains
(SH3 and SH2 domains), and a kinase domain. The Src SH2 domain is a relatively small protein
module of approximately 100 amino acids and has extraordinary ability to recognize
specifically sequences containing phosphotyrosine residue (pTyr), thereby facilitating
phosphorylation-dependent protein–protein interactions that result in signal transduction
process [3]. Short peptide inhibitors capable of disrupting these interactions have been designed
as useful tools in the mechanistic studies of the Src SH2 domain interactions and as potential
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inhibitors for further pharmaceutical development [4−8]. The Src SH2 domain preferentially
binds peptides with the sequence pTyr-Glu-Glu-Ile (pYEEI) with high affinity [9].
The use of conformationally constrained peptides has been shown to be an effective strategy
in developing therapeutic peptidic and peptidomimetic agents [10,11]. Constrained peptides
are usually more stable towards enzymatic degradations. We previously reported the synthesis
and evaluation of a series of covalently bonded conformationally constrained peptide analogues
based on the optimal sequence pYEEI as inhibitors of the Src SH2 domain [8]. A number of
conformationally constrained peptides showed at least 100-fold fold increase in the binding
affinities to the Src SH2 domain relative to pYEEI and the corresponding linear peptides,
respectively. The enhancement in binding affinities was accomplished solely through covalent
bonding of N-terminal and side chain functional groups, formation of a favorable conformation,
reducing unfavorable entropic effects, and/or creating novel bonding interaction between the
peptides and the protein. However, the conformational changes were irreversible; the synthesis
was cumbersome and challenging; and the preparation of the corresponding linear peptides
was necessary for comparative studies.
To minimize one or more of the problems associated with covalent bonding described above,
we attempted to introduce the conformational constraints through non-covalent forces by
incorporating groups capable of forming of intramolecular hydrogen bindings or chelating to
metals.
Metal-chelating groups have been used in the areas of protein purifications [12,13], peptide/
protein engineering [14,15], and designing of nucleic acid probes targeting specific DNA
molecules [16].
Hochuli and coworkers reported a novel nitrilotriacetic acid quadridentate chelate resin for
metal chelate affinity chromatography. It was found that when charged with Ni2+, the resin
was able to bind peptides and proteins containing neighboring histidine residues [12].
Hopkins group reported that transition metal could induce a conformational change in the α-
helical peptides bearing IDA groups at the i and i+3 or 4 positions [17]. The cooperative binding
of the two IDA groups to one transition metal could cross-link the peptide intramolecularly
and stabilize the secondary structure. The non-natural amino acid Fmoc-Lys(IDA)-OH was
used in the conventional Fmoc peptide synthesis and introduced into protein-peptide interaction
studies of the S-peptide fragment (α-helix rich) of ribonuclease S complex [18].
In a recent report from Syntrix Biosystems, Inc., probes where the N and C termini of a PNA
oligomer are modified with a pair of metal-chelating ligands (IDA or nitrilotriacetic acid, NTA)
were described, and it was found that the coordination can force the PNA oligomer into a
macrocyclic configuration [16]. The intramolecular chelate dissociates only when the PNA
hybridizes to its perfectly matched DNA target.
As part of our ongoing studies of interactions of conformationally constrained phosphopeptides
with the Src SH2 domain [8], herein we report the interactions of phosphopeptides containing
metal chelating groups with the Src SH2 domain in the presence and absence of metals. Peptide
Ac-K(IDA)pYEEIEK(IDA) (1, Figure 1) was structured to incorporate two iminodiacetate
groups (IDA), a common metal-chelating ligand, at the N- and C-terminal lysine residues,
flanking the pYEEI motif. The peptide was expected to achieve a constrained conformation
through potential intramolecular hydrogen bindings or chelating of the IDA groups with metal
ions. The binding affinity of the ligand toward the Src SH2 domain was determined in the
absence or presence of Ni2+ and/or a metal scavenger. The free amino groups in lysine residues
are also strong hydrogen bond donors and metal chelating groups. Three other peptides (Figure
1) containing 0 or 1 IDA group at one of the N- or C-terminal lysine residues, Ac-KpYEEIEK
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(2), Ac K(IDA)pYEEIEK (3), and Ac-KpYEEIEK(IDA) (4), were also synthesized and
evaluated for their binding affinities toward the Src SH2 domains.
2.0. Materials and Methods
2.1. Peptide Synthesis
All reactions were carried out in Bio-Rad polypropylene columns by shaking and mixing, using
a VWR rotator, at room temperature. All reagents were purchased from Novabiochem (San
Diego, CA), unless otherwise noted.
The peptides (Ac-K(IDA)pYEEIEK(IDA), Ac-KpYEEIEK, Ac-K(IDA)pYEEIEK, Ac-
KpYEEIEK(IDA), and Fluorescein-K(IDA)pYEEIEK(IDA)) were synthesized on a Rink
amide NovaGel resin employing N-(9-fluorenyl)methoxycarbonyl (Fmoc)-based chemistry
and Fmoc-L-amino acid building blocks. The synthesis of Fmoc-Lys(IDA)-OH has been
previously described [19]. The preparation of peptides containing the IDA moiety was carried
out according to the previously described procedure [15] using Fmoc-Lys(IDA(OtBu))-OH as
the building block. HBTU and DIPEA (TCI America, Portland, OR) in N,N-
dimethylformamide (DMF) (VWR, West Chester, PA) were used as coupling and activating
reagents, respectively. Fmoc deprotection at each step was carried out using piperidine (EMD,
La Jolla, CA) in DMF (20%). After the final coupling, the peptides were N-terminally
acetylated with acetic anhydride (Sigma-Aldrich, Milwaukee, WI), unless otherwise noted.
Assembled peptides were cleaved from the resin with TFA/water/TIS (Sigma-Aldrich)
(95:2.5:2.5) for 3 h, hydrolyzed for 19 h after addition of 10% water as described previously
(Novabiochem Catalogue 2006/2007, 3.32), dried in vacuum, dissolved in water, and
lyophilized on a Labconco FreeZone 6 (Kansas City, MO). The crude peptides were purified
by HPLC (Waters Delta Prep 4000, Millipore, Billerica, MA) on a Phenonemex Gemini 10
micron C18 column (Torrance, CA) by elution at 20 mL/min using a gradient of 5–95%
acetonitrile (0.1% formic acid) and water (0.1% formic acid) over 30 min. The peptides had a
purity of >95% determined by HPLC as shown by analytical HPLC using a similar gradient
system and a flow rate of 1 mL/min. The collected fractions were analyzed by LC-MS
(Shimadzu LC-10; Waters Micromass Quattro II), and only fractions containing the pure
peptide were pooled and lyophilized. All peptides were characterized by LC-MS or SELDI-
TOF mass spectrometer.
Ac-Lys(IDA)-pTyr-Glu-Glu-Ile-Glu-Lys(IDA) (1)—The peptide was prepared as
described above at 0.3 mmol scale and purified by HPLC in three separate batches. The final
overall yield was 141 mg (36%). LC-MS (ESI-TOF) (m/z) for C52H78N9O27P calcd, 1291.5;
found, 1291.7 [M]+.
Ac-Lys-pTyr-Glu-Glu-Ile-Glu-Lys (2)—The peptide was prepared as described above at
0.095 mmol scale and purified by HPLC. The final overall yield was 38 mg (38%). LC-MS
(ESI-TOF) (m/z) for C44H70N9O19P calcd, 1059.5; found, 1059.6 [M]+.
Ac-Lys(IDA)-pTyr-Glu-Glu-Ile-Glu-Lys (3)—The peptide was prepared as described
above at 0.085 mmol scale and purified by HPLC. The final overall yield was 12 mg (12%).
LC-MS (ESI-TOF) (m/z) for C48H74N9O23P calcd, 1175.5; found, 1176.0 [M + H]+.
Ac-Lys-pTyr-Glu-Glu-Ile-Glu-Lys(IDA) (4)—The peptide was prepared as described
above at 0.085 mmol scale and purified by HPLC. The final overall yield was 25 mg (25%).
LC-MS (ESI-TOF) (m/z) for C48H74N9O23P calcd, 1175.5; found, 1175.9 [M + H]+.
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Fluorescein-Lys(IDA)-pTyr-Glu-Glu-Ile-Glu-Lys(IDA) (5)—The peptide was prepared
as described above at 0.063 mmol scale. After the final Lys(IDA) coupling and Fmoc
deprotection, 5,6-carboxyfluorescein succinimidyl ester (33 mg, 0.070 mmol) and DIPEA
(0.066 mL, 0.25 mmol) were added to the swelled resin in DMF (1 mL) and the mixture was
shaken overnight in light-protected column. After the solution was drained, the resin was
washed with DMF (3 × 20 mL), and the fluorescein coupling was repeated overnight. After
the solution was drained, the resin was washed with DMF (4 × 20 mL). The peptide was cleaved
and purified by HPLC as described above. All the fractions were protected from light. The
final overall yield was 11 mg (11%). LC-MS (ESI-TOF) (m/z) for C71H86N9O32P calcd,
1607.5; found, 1609.2 [M + H]+; MS (SELDI-TOF) (m/z) for C71H86N9O32P calcd, 1607.5;
found, 1606.3 [M − 1]+, 1629.2 [M + Na − 1] +, 1645.7 [M + K − 1] +,
2.2. UV Titration Assay
All spectra were collected on a Beckman Coulter DU-800 UV-Vis spectrophotometer with a
scan rate of 120 nm/s, a slit width of 2 mm, and using 1 cm UV-Cuvette semi micro cells at
pH = 8.5 from 210 to 310 nm. Difference titration experiments were performed by subtracting
the signal of a cuvette containing only buffer solution from the signal of a similar solution
containing 10 µM NiCl2 after adding equivalent aliquots of the peptide solution to both
cuvettes. The extinction coefficients of the complexes were calculated from the initial slopes
of the titration curves and were based on the total metal concentration. In another set of
experiments, the Kd values were determined by monitoring the changes at 225 nm absorbance
of solutions of 10 µM peptide upon addition of aliquots of NiCl2 up to a final concentration of
10 µM.
2.3. Expression and Purification of the Src SH2 Domain
Bacterial DH5α cells containing recombinant plasmid pGEX-Src-SH2 domain were used to
inoculate 500 ml of Luria-Bertani (LB) culture medium. After 10–12 h culture at 37 °C , the
bacterial culture (OD600nm around 1.0) was cooled down to 25 °C and diluted by another 500
mL of LB medium. Then 0.4 mM isopropyl β-D-isogalactopyranoside (IPTG) was added to
induce the production of the fusion protein for 7 h at 25 °C. After induction, the bacterial cells
were harvested by centrifugation at 5000 rpm for 5 min at 4 °C. Then bacterial pellets were
resuspended in 50 mL 1X PBS and sonicated for 15 sec. Resupension and sonication were
repeated 5 times. All cell debris, including insoluble proteins, were removed by centrifugation
at 20,000 rpm for 30 min. The supernatant was mixed and incubated with 0.1 g of glutathione-
agarose resin for 1 h and loaded into purification column. When all liquid portions flowed
through the column, 1 or more column volumes of PBS was used to wash the glutathione-
agarose resin, which had already bound to the fusion protein GST-tagged Src SH2 domain,
until no proteins can be detected in the flow-through by Bradford protein reagent. In order to
adjust the pH of the resin from 7.4 to 8.0, another 1 volume of 50 mM tris buffer (pH 7.4) and
1 volume of 50 mM tris buffer (pH 8.0) were used to wash the beads. Reduced L-glutathione
(10 mM) in 50 mM tris (pH 8.0) buffer was used to elute the fusion protein. All purification
steps were carried out at 4 °C. Protein concentrations were determined by Bradford protein
assay using bovine serum albumin as a standard.
2.4. Fluorescence Polarization Binding Assay
2.4.1. Competitive Fluorescence Polarization Binding Assay in Presence of the
Src SH2 Domain—All peptides were tested as competitors of the fluorescent probe F-
GpYEEI for binding affinity to the Src SH2 domain using fluorescent polarization (FP)
competitive binding assay as described below. FP intensities were measured at 25 °C in a
disposable glass tube (volume of 600 µL) using a Perkin-Elmer LS 55 luminescence
spectrometer equipped with an FP apparatus. The excitation and emission wavelengths were
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set at 485 and 535 nm, respectively. For the competition assay, final concentrations of 80 nM
fluorescent probe F-GpYEEI, 750 nM Src SH2 domain, phosphate buffer (20 mM, pH 7.3,
100 mM NaCl, 2 mM DTT, 0.1% BSA), water, and various concentrations (0 − 100 µM) of
each competitor peptide were used. The order of addition to each glass tube (600 µL) was (i)
buffer, (ii) water, (iii) fluorescent probe, (iv) Src SH2 domain, and (v) competitor peptide. A
blank control (with the Src SH2 domain but without a peptide) and a background control
(without both the Src SH2 domain and the peptide) were used. The inhibition percentage of
fluorescence probe binding to the Src SH2 domain by the sample was calculated by the
following equation:
where FPblk is the fluorescent polarization value of the blank control. FPs is the fluorescent
polarization value of the sample (peptide), and FPbgd is the fluorescent polarization value of
the background control. The inhibition percentages of the various concentrations of the assayed
peptides were plotted, and the Kd value (the concentration of peptides at which the binding site
on Src SH2 domain is half occupied) was calculated using LAB Fit Curve Fitting Software
7.2. The reported Kd values are the mean of three separate determinations with a standard
deviation of less than 5%.
2.4.2. Competitive Fluorescence Polarization Binding Assay in Presence of the
Src SH2 Domain and Different Metal Ions—The assays were performed as described
above with the exception that the metal ions with different final concentrations [NiCl2 (2, 5,
10, 50, 100, 200, 300 and 500 µM), CoCl2, CdCl2, CuCl2, and ZnSO4 (2 and 300 µM)], were
added after addition of the competitor peptides. In another set of assay, EDTA (300 µM) was
also used after the addition of the same concentration of Ni2+ and incubated for 10 min.
2.4.3. Saturation Binding Assay Using Fluorescein-Labeled Peptide 5—
Fluorescein-labeled peptide 5 (80 nM) was used in the presence of Ni2+ alone at different
concentrations (0.08, 0.16, 0.32, 0.64, 1, 3, 10, 30, 100, 200, 300, 400, and 500 µM). In another
experiment, F-GpYEEI (80 nM) was used in the place of peptide 5 as a control peptide. The
same assay was carried out in the presence of a similar amount of EDTA added to each
concentration point of Ni2+ described above. The Src SH2 domain had a fixed concentration
of 0.75 µM in all experiments.
2.5. Circular Dichroism (CD) Spectroscopy
All CD spectra were recorded in 1 cm path length cuvette on a nitrogen-flushed JASCO J-810
spectropolarimeter interfaced with a 25 °C water bath by averaging six consecutive scans. All
spectra were recorded with a 4 ms response and a bandwidth of 1 nm. CD spectra were measured
with the spectropolarimeter using a 50 nm.min−1 scan speed. All spectra were corrected for
background by subtraction of appropriate blanks. The data are represented in the 185−265 nm
spectral range.
3.0. Results and Disucssion
3.1. Chemistry
Peptides containing 0–2 IDA groups (Figure 1) were synthesized by solid-phase Fmoc-based
chemistry employing Rink amide NovaGel resin as the solid support and Fmoc-L-amino acids
as building blocks. The synthesis of Fmoc-Lys(IDA)(OtBu)-OH has been previously reported
[19]. The synthesis of peptide 1 is shown as a representative example in Scheme 1 using Fmoc-
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Lys(IDA(OtBu))-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ile-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Glu
(OtBu)-OH, Fmoc-Tyr(H2PO3)-OH, and Fmoc-Lys(IDA(OtBu))-OH, respectively, in
coupling reactions with the resin. 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU) and N,N-diisopropylethylamine (DIPEA) in N,N-
dimethylformamide (DMF) were used as coupling and activating reagents, respectively. Fmoc
deprotection at each step was carried out using piperidine in DMF (20%). After the final
deprotection, the peptides were capped by N-terminal acetylation with acetic anhydride. Then
a mixture of trifluoroacetic acid (TFA):water:triisopropylsilane (TIS) (95:2.5:2.5) was used
for side chain deprotection of amino acids and cleavage of the synthesized peptide from the
resin. Finally, the resin was hydrolyzed for 19 h after addition of 10% water, dried in vacuum,
and lyophilized. The crude peptides were purified by preparative reverse-phase HPLC and
analyzed by LC-MS using a gradient of 5–95% acetonitrile (0.1% formic acid) and water (0.1%
formic acid) at 20 mL/min over 30 min. The purity of final products was confirmed by analytical
HPLC (>95%) using a similar gradient system at 1 mL/min. A similar protocol was also used
for the synthesis of peptides 2–5 using appropriate Fmoc-amino acid building blocks or 5,6-
carboxyfluorescein succinimidyl ester.
3.2. UV Titration Studies
UV Titration studies were carried out to determine whether Ni2+ binds to the peptides. Different
concentrations of peptide 1 (1 to 100 µM) were incubated with a fixed concentration of 10 µM
Ni2+ (Figure 2a). In a lower range of peptide concentration (<10 µM) and less than one
equivalent of Ni2+ concentration, the monitored absorbance was concentration-dependent and
increased consistently. However, at higher concentrations of the peptide (>15 µM), the
absorbance reached its steady state, suggesting that Ni2+ ions was already saturated with
peptides.
When the Δε was plotted with different equivalents (from 0 to 10) of peptide 1, the curve was
consistent with the formation of a 1:1 metal-peptide complex (Figure 2b). This indicates that
the two IDA groups on the N- and C-termini can possibly interact with one Ni2+ ion and form
a cyclic peptide-metal chelation complex. However, other peptide-metal complex species, such
as those resulting from intermolecular interactions between the peptide and a Ni2+ ion in 1:2
metal-peptide complex, may also be present at higher concentrations of the peptide. The
conformation and the binding profile of this cyclic complex were further investigated by using
CD and fluorescence polarization studies.
The difference absorption spectra of free and metal-bound cyclic peptide 1 demonstrated that
the absorbance at ~225 nm can be used to monitor the formation of peptide-metal complex
(Figure 2c). The Kd was determined to be 234.7 nM using the Igor Pro algorithm by plotting
the absorbance change at specific wavelength versus concentration of peptide upon addition
of aliquots of Ni2+ from an aqueous stock.
Peptide 2 containing two unsubstituted lysine residues exhibited the highest binding affinity
toward Ni2+ (Kd = 97.4 nM) (Table 1) when compared with other peptides. Peptides 3 and 4
also exhibited higher binding affinity toward Ni2+ when compared with peptide 1, possibly
due to the presence of at least one free amino group that is a stronger chelating group than a
carboxylate. Control peptide Ac-pYEEI does not have a strong chelating group at the N- or
C-termini. Thus, Ac-pYEEI did not exhibit a high binding affinity toward Ni2+, suggesting
that the high affinity binding between peptide 1 and Ni2+ is not due to the interactions with
negatively-charged phosphate group.
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3.3. Fluorescence Polarizaton (FP) Binding Assay
3.3.1. Competitive Binding Assay in Presence of the Src SH2 Domain—The
binding affinities of the synthesized peptides 1−4 along with Ac-pYEEI against the Src SH2
domain were determined and compared in the presence of the reference peptide probe, F-
GpYEEI, using a fluorescence polarization competitive assay. The results expressed as Kd
values are shown in Table 2.
Peptide 1 with two IDA groups at the N- and C-terminal lysine residues showed 2.7-fold higher
binding affinity toward the SH2 domain when compared with the optimal sequence Ac-
GpYEEI. These data suggest that the carboxylic groups on the IDA groups may have
contributed to the binding to the Src SH2 domain binding pockets, possibly through additional
hydrogen bonding or electrostatic interactions. Furthermore, the introduction of the two
negatively charged IDA groups may have generated a favorable conformational change within
modified pYEEI derivative for appropriate binding to the SH2 domain.
The crystal structure of the Src SH2 domain complexed with peptide pYEEI showed two major
binding pockets within the domain substrate binding site, the hydrophilic pTyr binding pocket
(P site) and the hydrophobic pocket (P+3 site) [3]. The glutamic acid residues (EE) in the P+1
and P+2 positions have minor interactions with amino acids in the SH2 domain. The two lysine
residues in peptide 1 are located at the P−1 and P+5 positions, and may have minor interactions
with other small binding grooves or other important amino acids outside the P and P+3 sites.
Further structural studies are required to identify the key amino acids outside these two major
binding pockets that are involved in interactions with IDA groups. That information may
provide insights for designing more potent Src SH2 domain binding ligands.
Peptide 2, which lacks the two IDA groups but has the two lysine residues at both terminals,
had a Kd value of 52.70 µM showing significant decrease in the binding affinity when compared
with peptide 1 and Ac-pYEEI. The reduction of binding affinity in 2 suggests that the presence
of positively-charged amino acid residues at both N- and C-termini is detrimental to interactions
with the SH2 domain. Incorporation of one IDA group at the N- or C-terminal in peptides 3
and 4 rescued partially the binding affinity when compared with peptide 2. However, peptides
3 and 4 showed approximately 5-fold lower binding affinity toward the SH2 domain when
compared with that of peptide 1 containing two IDA groups. These data suggest that the
presence of two positively-charged lysine residues at either the N- or C-terminals is deleterious
in interactions with the SH2 domain. On the other hand, the presence of one or two IDA groups
can provide additional interactions with amino acid residues existing on both sides of the
binding pocket regions of the Src SH2 domain leading to enhanced binding affinity of the
peptides toward to the SH2 domain.
3.3.2. Competitive Binding Assay in Presence of the Src SH2 Domain and
Different Metal Ions—Table 3 shows that by incubating peptide 1 in the presence of different
concentrations of Ni2+ (0–500 µM for peptide 1), the binding affinities toward the Src SH2
domain consistently decrease. The binding affinity of peptide 1(Kd = 0.6 µM) was reduced by
more than two fold (Kd = 1.6 µM) upon addition of Ni2+ (300 µM). This binding affinity is
similar to the Kd value of Ac-pYEEI, suggesting that Ni2+ possibly causes some structural
effects on the binding pocket of the protein or blocks the interactions of the carboxylate groups
with the SH2 domain through the formation of a complex between the two IDA groups and
Ni2+.
These data were consistent with the results of UV titration studies showing the formation of a
1:1 complex between peptide 1 and Ni2+ with a Kd value of 234.7 nM. In the experimental
conditions of the fluorescence polarization assay while free peptide and peptide-metal complex
coexist, the binding affinity of peptide 1 is approximately 7-fold lower toward the SH2 domain
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than Ni2+. On the other hand, even at the highest concentration of Ni2+ (500 µM), the peptide
retained a high binding affinity for the Src SH2 domain. It is not clear from these experiments
whether the peptide-metal complex binds to the SH2 domain in a similar manner to peptide
1. One direct method to determine whether peptide 1 and the peptide-metal complex bind to
the Src SH2 domain in the cyclized form is to synthesize a covalently cyclized peptide by
linking between the two IDA groups or two lysine residues and compare the binding affinity
with the peptide 1 in the presence of Ni2+. Unfortunately, the synthesis of the covalently
cyclized peptide was not successful by using standard methods. Further studies, such as
synthesizing a new class of cyclized peptides with different ring sizes, are required to
understand effect of the ring size and the role of the lysine residues in the binding to the Src
SH2 domain.
To further prove the effect of the peptide-metal complex formation on the binding affinity of
peptide 1 to the Src SH2 domain, FP assay was conducted by adding the same concentration
of EDTA (300 µM) to the system containing 300 µM Ni2+. As shown in Table 3, upon adding
EDTA to the system, the binding affinity of peptide 1 was almost restored to the original level,
changing the Kd value from 1.55 to 0.79 µM. EDTA was a very effective competitive chelating
agent with a much higher affinity than peptide 1 for binding to Ni2+. It is possible that EDTA
reversed the structural effect of Ni2+ on the protein. Another possibility is that most of the
peptide in the peptide-Ni2+ complex was replaced by EDTA, forcing the peptide 1 to return to
the unbounded free state for optimal interaction with the SH2 domain.
Similarly the addition of Ni2+ ions (0, 2 and 300 µM) to peptides 2−4 slightly affected the
Kd values. These data suggest that the addition of Ni2+ did not significantly change the pattern
of interactions for peptides 2−4 with the Src SH2 domain and the changes were believed to be
caused by Ni2+ addition only. The Ni2+ ion itself may have caused some structural effects on
the Src SH2 domain that may have eventually affected the binding with the peptides. This
phenomenon was shown in the CD experiments described later.
To test the hypothesis, other types of transition metals were selected, including Co2+, Cd2+,
Cu2+, and Zn2+, and used in similar experimental conditions (Table 4). Interestingly, only
Co2+ showed similar binding patterns when compared to Ni2+ at 2 and 300 µM. All other
metals, Cd2+, Cu2+, and Zn2+, showed deleterious effects in the assay at both 2 and 300 µM
conditions. Even at 2 µM of Cd2+, Cu2+, and Zn2+, the FP values revealed that there were no
binding interactions of F-GpYEEI to the Src SH2 domain, possibly due to the partial or
complete denaturation/ structural changes of the Src SH2 domain and/or changing the
conformation of the protein binding sites in the presence of these metals. It is not clear why
this type of protein structural modifications do not happen in the presence of Ni2+ and Co2+,
but could be related to the physicochemical properties of the metals and their differences in
interactions with the SH2 domain.
3.3.3. Saturation Binding Assay Using Fluorescein-Labeled Peptide 5—
Fluorescein-labeled peptide 5 (Figure 1) was synthesized and used as a probe instead of F-
GpYEEI to study the interactions of peptide containing two IDA groups with Ni2+ in the
presence of EDTA or the Src SH2 domain. Several different FP studies were performed, such
as assays of peptide 5 with Ni2+, peptide 5 with Ni2+ in the presence or absence of same
concentration of EDTA, and peptide 5 with Ni2+ in the presence of a fixed concentration of
the Src SH2 domain. F-GpYEEI with Ni2+ was used as a control.
As shown in Figure 3, the control peptide F-GpYEEI did not show any dramatic change in FP
values upon addition of Ni2+ even at high concentration of 500 µM. This result was expected
since Ac-pYEEI had very weak affinity toward Ni2+ as described above. However, peptide 5
showed a significant increase in FP values in the presence of Ni2+ when compared with F-
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GpYEEI, suggesting the formation of peptide-metal complex in the assay condition. To explain
this observation, the same concentration of EDTA was added to the assay system. In the
presence of the metal scavenger, the FP values showed no significant changes at different
concentrations of Ni2+, meaning that EDTA disrupted the complex formation of peptide 5
through chelating with Ni2+.
As described above, the interaction between peptide 1 and the Src SH2 domain was slightly
disrupted upon the addition of high concentrations of Ni2+ (Kd changed from 0.63 to 1.55 µM).
Peptide 5 showed a similar binding disruption pattern in the presence of the Src SH2 domain
as shown by the reduced fluorescence polarization values with increasing Ni2+ concentrations
(Figure 3). Similarly, fluorescent-labeled peptide 5 was still able to bind to the Src SH2 domain
even at 500 µM of Ni2+. The presence of the fluorescein group at the N-terminal of peptide 5
may have partially changed the conformation of the optimal interaction with the SH2 domain.
3.4. Circular Dichroism (CD) Spectroscopy Study
3.4.1. CD Studies of Peptides with Different Concentration of Ni2+ in the Absence
of the Src SH2 Domain—Peptide 1 showed similar folded conformations at different
concentrations of Ni2+ (0–500 µM) (Figure 4). The peptide showed a significantly folded
structure in the absence of the metal based on the elipticity values and retained its secondary
structure in the presence of Ni2+. This result was not surprising since the binding affinity of
peptide 1 to the SH2 domain was slightly decreased in the presence of Ni2+. In other words,
Ni2+ did not disrupt the conformation of peptide 1 significantly for interaction with the SH2
domain. This may explain why peptide 1 itself was able to bind to the Src SH2 domain with a
higher binding affinity than Ac-pYEEI. The addition of two IDA groups may have assisted the
peptide to adopt a favorable conformation for the interaction with the Src SH2 domain. The
addition of Ni2+ partially disrupted the interaction of IDA groups with the SH2 domain, but it
did not change the conformation of the peptide since the folding of the peptide was not
disturbed. Peptide 1 appears to have an appropriate folded structure in the absence of Ni2+ and
addition of the metal did not change the secondary structure during the interaction with the
SH2 domain.
Peptide 2 exhibited a much lower binding affinity to the SH2 domain because of the importance
of the IDA groups versus the positively-charged amino groups. Peptide 2 was folded much
less compared to 1 in the absence of the metal based on the elipticity values. Addition of 5 µM
Ni2+ to 2 enhanced the elipticity values. As shown in Table 3, the binding affinity of 2 increased
in the presence of 300 µM of Ni2+ (Kd = 39.3 µM), suggesting the folding of this peptide in
the presence of the high concentration of the metal may have assisted the interaction with the
SH2 domain. Peptide 2 showed more folding in the presence of Ni2+, but compared to peptide
1, elipticity values were lower even at the highest concentrations of Ni2+. This was mainly
because the amino groups of peptide 2 can also chelate to Ni2+.
Peptides 3 and 4 showed similar pattern to 1 with a minor increase of elipticity in the presence
of Ni2+. However, their elipticity values were higher than peptide 2. In general, it appears that
peptides 1, 3 and 4 have secondary structures with higher elipticities than that of peptide 2 and
their secondary structures are not affected significantly in the presence of Ni2+.
3.4.2. CD Studies of the Src SH2 Domain (Fixed Concentration) in the Presence
of Different Concentrations of Ni2+—Slight enhancement in elipticity of the Src SH2
domain was observed in the presence of Ni2+, suggesting that this metal affects the secondary
structure of Src SH2 domain (Figure 5). Because of there are several types of secondary
structures in the Src SH2 domain, including α-helices and β-sheets, the peaks are broader from
200–230 nm with a minimum at 210 nm.
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3.4.3. CD Studies of Fixed Concentration of Peptides and the Src SH2 Domain
with Different Concentrations of Ni2+—Similar equivalents of the peptides and SH2
domain were used with different concentrations of Ni2+ in similar ratios as the other
experiments described above (Figure 6). In general, the changes in the secondary structures
appear to be from the effect of Ni2+ on the Src SH2 domain and not because of the interaction
of the peptide with the Src SH2 domain. Comparing the spectra with those of the Src SH2
domain alone in the presence of Ni2+ (Figure 5) shows that the differences are not significant.
These data were consistent with the binding affinity data that showed lower binding affinity
in the presence of Ni2+, possibly because of the changes in the secondary structure of the Src
SH2 domain at high concentrations of the metal. Peptides 1, 3, and 4 showed some elipticity
enhancement after 1–1.5 µM of Ni2+. At higher concentrations of Ni2+, there was no significant
change for the peak with the minima of 210 nm. Peptide 2 exhibited larger changes up to 1.5
µM of Ni2+.
4.0. Conclusions
Herein, we introduced novel peptides containing 0–2 IDA groups at the side chains of lysine
residues flanking the optimal sequence of the Src SH2 domain ligand pYEEI to introduce
conformational constraints through non-covalent forces, such as intramolecular hydrogen
bindings or metal chelation. UV titration studies demonstrated that all four peptides were
capable of chelating with one Ni2+ ion possibly by formation of a cyclic complex. However,
only peptide 1 showed 2.7-fold higher binding affinity toward the SH2 domain when compared
with the optimal sequence Ac-GpYEEI. Although CD experiments did not show significant
changes in the structure of the peptide in the absence or presence of Ni2+, the increased affinity
when compared to the reference peptide Ac-pYEEI indicated that the addition of IDA groups
at the two terminals may have already caused the formation of a favorable conformation for
peptide 1 for binding to the Src SH2 domain. The non-covalent interactions between the two
IDA groups within peptide 1 could explain the lack of dramatic effect of Ni2+ ion on the ligand
binding affinity toward SH2 domain. Ni2+ could serve as a bridge to bring the two IDA groups
together, achieving similar conformational effect as that via direct inter-IDA group interactions
in the absence of Ni2+. Furthermore, based on the CD experimental data, Ni2+ caused the
structural disruption on the protein and thus modest effect on the peptide-SH2 domain binding
interaction. FP assays showed a 2 fold decrease of the binding affinity for the Src SH2 domain
for peptide 1 when Ni2+ was added to the system at high concentration of 300–500 µM.
Nonetheless, the addition of EDTA dropped the Kd value back to the almost original level,
suggesting the disruption is reversible. In future studies, optimized substrate sequences from
other protein families may be used to construct IDA containing substrate peptides. With further
optimization, this class of peptides may serve as potential SH2 domain binding ligands.
Abbreviations
IDA, iminodiacetate; F-GpYEEI, fluorescein-labeled GpYEEI; FP, fluorescence polarization;
CD, circular dichroism..
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Figure 1.
Chemical structures of peptides 1−4 containing 0–2 IDA groups and fluorescein-labelled
peptide derivative 5.
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Figure 2.
(a) UV titration of peptide 1 (1–100 µM) with a solution of Ni2+ (10 µM). The data are plotted
as Δε versus wavelength. (b) The Δε versus equivalents of peptide 1 (0–10 equiv). One
equivalent of Ni2+ interacts with one equivalent of peptide 1. (c) Difference absorption spectra
of free and metal-bound peptide 1. Free peptide 1 (10 µM) (black); Ni2+-bound peptide: peptide
1 (10 µM) with NiCl2 (10 µM) (red).
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Figure 3.
The fluorescence polarization values in different saturation assay conditions.
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Figure 4.
The CD spectra of peptides 1–4 (100 µM) in the presence of different concentrations of Ni2+
in the absence of the Src SH2 domain.
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Figure 5.
The CD spectra of different concentration of Ni2+ and fixed concentration of Src SH2 domain.
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Figure 6.
The CD spectra of fixed concentration of peptides 1−4 and the Src SH2 domain with different
concentrations of Ni2+.
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Scheme 1.
Solid-phase synthesis of peptide 1.
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Table 1
The Binding Affinity of Peptides 1–4 to Ni2+.
Peptides Kd (nM)
a
AcpYEEI >600
1 234.7
2 97.4
3 153.2
4 161.9
a
Kd: The concentration of peptides (Ac-pYEEI or 1–4) at which half of them bind to Ni2+. Values are means of three experiments with a standard
deviation of less than ± 5%.
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Table 2
Binding Affinity of Peptides Containing IDA Group and Ac-pYEEI to the Src SH2 domain.
Peptides Kd (µM)
a
Ac-pYEEI 1.70
1 0.63
2 52.70
3 2.96
4 3.35
a
Kd: The concentration of peptides (Ac-pYEEI or 1–4) at which the binding site at the Src SH2 domain is half occupied. Values are means of three
experiments with a standard deviation of less than ± 5%.
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Table 3
Binding Affinity of the Peptides Containing 0–2 IDA Groups (1–4) toward the Src SH2 Domain in the Presence of
Ni2+.
Compounds Ni2+(µM) Kd (µM)
a
1 0 0.63
1 2 0.69
1 5 1.02
1 10 1.08
1 50 1.18
1 100 1.15
1 200 1.07
1 300 1.55
1 500 1.45
1 (300 µM EDTA) 300 0.79
2 0 52.70
2 2 55.68
2 300 39.30
3 0 2.96
3 2 2.98
3 300 3.70
4 0 3.35
4 2 4.13
4 300 4.01
a
Kd: The concentration of peptides (AcpYEEI or 1–4) at which the binding site at the Src SH2 domain is half occupied. Values are means of three
experiments with a standard deviation of less than ± 5%.
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Table 4
Binding Affinity of Peptide 1 toward the Src SH2 Domain in the Presence of Different Concentration of Metals
(Co2+, Cd2+, Cu2+, and Zn2+).
Compounds Kd (µM)
a
1 (2 µM Co2+) 1.09
1 (with 300 µM Co2+) 2.55
1 (with 2 µM Cd2+, Cu2+ or Zn2+) NAb
1 (with 300 µM Cd2+, Cu2+ or Zn2+) NAb
a
Kd: The concentration of peptides (AcpYEEI or 1–4) at which the binding site at the Src SH2 domain is half occupied. Values are means of three
experiments with a standard deviation of less than ± 5%
b
NA = no binding of F-GpYEEI with the Src SH2 domain was observed after metal addition.
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